David McMullin has served as our Chief Business Officer since October 2020 and as an executive officer of the company since 2018. He is responsible for corporate strategy, business development, investor relations, communications, business operations including HR and IT, medical affairs, and commercialization. Mr. McMullin has more than 20 years of experience leading global commercialization, business development, and strategic planning operations in the biopharmaceutical industry. After joining Aldeyra as SVP Corporate Development and Strategy in 2018, he was appointed Chief Commercial Officer in January 2019, and named to the expanded role of Chief Business Officer in October 2020. Prior to Aldeyra, Mr. McMullin was Group Vice President and Head of U.S. Internal Medicine at Shire plc, a $1.4 billion commercial business unit. He also ran Global Commercial Operations at Shire and was an in-line Committee member responsible for commercial performance and execution worldwide. Prior to his work at Shire, Mr. McMullin held roles of increasing responsibility in corporate strategy, sales, marketing, and operations at Novartis AG and worked as a business strategy consultant at Charles River Associates. Mr. McMullin received an M.B.A. from Harvard Business School, and a B.S. in Economics from Brigham Young University.
Back to Leadership Team & Board of Directors